Consensus DiaMedica Therapeutics Inc.

Equities

DMAC

CA25253X2077

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-03 EDT			5-day change	1st Jan Change
3 ^USD	+14.07%		+16.73%	+5.63%

04-17	DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	MT
04-17	DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	CI

Evolution of the average Target Price on DiaMedica Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

df400a84e3b9111e385378cba355ce59.P-L1X3D5xjVMkyJ23aFsXGAY30vwkYhyFGnk45uiZo8.aZaDPS-7_m0NpXM0ucQ0ZCtCr36D-OYLYhy-zu2UK8NNpLQxG5ecd3v6RQ~b977d7c8f445500d25e5ce246afb0b0b

Analyst Recommendations on DiaMedica Therapeutics Inc.

Craig Hallum Cuts DiaMedica Therapeutics Price Target to $8 From $11, Maintains Buy Rating	03-21	MT
Oppenheimer Trims DiaMedica Therapeutics Price Target to $6 From $7, Maintains Outperform Rating	03-21	MT
Oppenheimer Upgrades DiaMedica Therapeutics to Outperform From Perform, $7 Price Target	23-06-22	MT
Oppenheimer Downgrades DiaMedica Therapeutics to Market Perform From Outperform	22-07-07	MT
Lake Street Trims DiaMedica Therapeutics' Price Target to $8 From $14, Keeps Buy Rating	22-07-07	MT
Craig Hallum Lowers DiaMedica Therapeutics' Price Target to $12 From $18, Keeps Buy Rating	22-07-07	MT
Roth Lowers Price Target for DiaMedica Therapeutics to $16 From $24, Maintains Buy Rating	22-05-05	MT
Oppenheimer Adjusts DiaMedica Therapeutics' Price Target to $15 From $17, Maintains Outperform Rating	22-03-18	MT
Maxim Group Adjusts DiaMedica Therapeutics Price Target to $6 From $11, Maintains Buy Rating	22-02-02	MT
Oppenheimer Adjusts DiaMedica Therapeutics PT to $17 From $21, Maintains Outperform Rating	21-11-12	MT
DIAMEDICA THERAPEUTICS : Roth Capital Adjusts DiaMedica Therapeutics PT to $24 From $32, Maintains Buy Rating	21-09-27	MT
DIAMEDICA THERAPEUTICS : Maxim Group Adjusts Price Target on DiaMedica Therapeutics to $11 From $14, Reiterates Buy Rating	21-06-30	MT
DIAMEDICA THERAPEUTICS : Roth Capital Adjusts DiaMedica Therapeutics' Price Target to $32 From $38, Maintains Buy Rating	21-06-29	MT
DIAMEDICA THERAPEUTICS : Oppenheimer Starts DiaMedica Therapeutics at Outperform With $27 Price Target	21-04-09	MT
DIAMEDICA THERAPEUTICS : Craig-Hallum Adjusts Price Target on DiaMedica Therapeutics to $20 From $15, Maintains Buy Rating	21-03-12	MT
DIAMEDICA THERAPEUTICS : Roth Capital Initiates Coverage on DiaMedica Therapeutics at Buy, Sets Price Target at $38	21-02-17	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3 USD

Average target price

7 USD

Spread / Average Target

+133.33%

High Price Target

8 USD

Spread / Highest target

+166.67%

Low Price Target

6 USD

Spread / Lowest Target

+100.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering DiaMedica Therapeutics Inc.

Oppenheimer
Craig-Hallum
Lake Street
Roth Capital Partners
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar